Kura Oncology, Inc.
KURANASDAQHealthcare● Active
$8.61
$-0.14(-1.54%)
Market Cap$763903411
P/E Ratio—
52W High$12.49
52W Low$5.45
Kura Oncology, Inc. (KURA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KURA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$0.83
Est. -$0.88 · +5.7%
Revenue
$0.02B
Est. $0.03B · -29.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 1-Quarter EPS Beat Streak
KURA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.91 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 12, 2026 | -$0.88 | -$0.83 | +5.7% | $0.02B | $0.03B | -29.7% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -$0.72 | -$0.92 | -27.8% | $0.02B | $0.04B | -51.1% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.57 | -$0.85 | -49.1% | $0.02B | $0.05B | -59.6% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.15 | -$0.75 | -600.0% | $0.02B | $0.06B | -76.5% |
| ▼ Q2 FY2025 | May 1, 2025 | -$0.51 | -$0.66 | -29.4% | $0.01B | $0.07B | -78.8% |
| ▲ Q1 FY2025 | Feb 26, 2025 | -$0.65 | -$0.22 | +66.2% | $0.05B | $0.06B | -7.0% |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.64 | -$0.63 | +1.6% | — | $0.06B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.91
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Beat
EPS Actual
-$0.83
EPS Est.
-$0.88
EPS Surpr.
+5.7%
Revenue
$0.02B
Q1 FY2026
Mar 5, 2026Miss
EPS Actual
-$0.92
EPS Est.
-$0.72
EPS Surpr.
-27.8%
Revenue
$0.02B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.85
EPS Est.
-$0.57
EPS Surpr.
-49.1%
Revenue
$0.02B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.75
EPS Est.
$0.15
EPS Surpr.
-600.0%
Revenue
$0.02B
Q2 FY2025
May 1, 2025Miss
EPS Actual
-$0.66
EPS Est.
-$0.51
EPS Surpr.
-29.4%
Revenue
$0.01B
Q1 FY2025
Feb 26, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.65
EPS Surpr.
+66.2%
Revenue
$0.05B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.63
EPS Est.
-$0.64
EPS Surpr.
+1.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.83 | $-0.61 | $-0.07 | 2 |
| Q3 FY2027 | $-0.93 | $-0.69 | $-0.07 | 2 |
| Q2 FY2027 | $-0.94 | $-0.69 | $-0.07 | 2 |
| Q1 FY2027 | $-0.97 | $-0.72 | $-0.08 | 2 |
| Q4 FY2026 | $-1.19 | $-0.89 | $-0.09 | 4 |
| Q3 FY2026 | $-1.02 | $-0.91 | $-0.82 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.1B | $0.1B | 7 |
| Q3 FY2027 | $0.0B | $0.1B | $0.1B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.1B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 12, 2026 | +5.7% | $9.51 | $9.68 | +1.79% |
| ▼ Q1 FY2026 | Mar 5, 2026 | -27.8% | $8.55 | $8.51 | -0.47% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -49.1% | $9.77 | $9.96 | +1.94% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -600.0% | $6.03 | $5.96 | -1.16% |
| ▼ Q2 FY2025 | May 1, 2025 | -29.4% | $6.56 | $6.49 | -1.07% |
| ▲ Q1 FY2025 | Feb 26, 2025 | +66.2% | $7.88 | $7.77 | -1.40% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +1.6% | $17.84 | $17.77 | -0.39% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +6.3% | $18.57 | $19.12 | +2.96% |
Q2 FY2026+1.79%
Report Date
May 12, 2026
EPS Beat/Miss
+5.7%
Price Before
$9.51
Price After
$9.68
Q1 FY2026-0.47%
Report Date
Mar 5, 2026
EPS Beat/Miss
-27.8%
Price Before
$8.55
Price After
$8.51
Q4 FY2025+1.94%
Report Date
Nov 4, 2025
EPS Beat/Miss
-49.1%
Price Before
$9.77
Price After
$9.96
Q3 FY2025-1.16%
Report Date
Aug 7, 2025
EPS Beat/Miss
-600.0%
Price Before
$6.03
Price After
$5.96
Q2 FY2025-1.07%
Report Date
May 1, 2025
EPS Beat/Miss
-29.4%
Price Before
$6.56
Price After
$6.49
Q1 FY2025-1.40%
Report Date
Feb 26, 2025
EPS Beat/Miss
+66.2%
Price Before
$7.88
Price After
$7.77
Q4 FY2024-0.39%
Report Date
Nov 7, 2024
EPS Beat/Miss
+1.6%
Price Before
$17.84
Price After
$17.77
Q3 FY2024+2.96%
Report Date
Aug 8, 2024
EPS Beat/Miss
+6.3%
Price Before
$18.57
Price After
$19.12
Avg Beat Reaction+0.74%
Avg Miss Reaction-0.19%
Beat Rate4 / 8 quarters
Largest Move+2.96% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KURA ends December
Kura Oncology, Inc. (KURA) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-0.83 — beating the analyst consensus of $-0.88 by +5.7%. The next KURA earnings date is expected around September 1, 2026.
Each quarter, investors track KURA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KURA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KURA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KURA earnings · 5 questionsKura Oncology, Inc.'s next earnings report is expected around September 1, 2026. KURA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KURA historically reports after market close (AMC).
KURA earnings datewhen is KURA earningsKURA next earnings datewhen does KURA report earningsKURA earnings calendar
▸ Source: FMP · Kura Oncology, Inc. SEC filings · US GAAP · Kura Oncology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026